

**Contact:**

Anthony Recupero, Ph.D.  
Vice President Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release*****MaxCyte to Speak at TERMIS North America 2007 Conference & Exposition***

*"Engineered Cellular Therapeutics: Optimizing Product Potency Utilizing Scalable Manufacturing Processes"*

**Gaithersburg, MD, June 13, 2007** – MaxCyte, Inc., a clinical stage therapeutics company and pioneer in cell loading systems, announces Madhusudan Peshwa, Ph.D., Vice President of Research & Development, will be a featured speaker at the TERMIS North America 2007 Conference & Exposition. The meeting is being held June 13 – 16, 2007 in Toronto, Canada.

Dr. Peshwa's presentation entitled "Engineered Cellular Therapeutics: Optimizing Product Potency Utilizing Scalable Manufacturing Processes" will discuss MaxCyte's technologies and clinical product development experiences with customizing biological activity of cellular therapeutics utilizing robust, closed system, scalable, cGMP compliant manufacturing processes for clinical / commercial delivery of safe and effective engineered cellular products. The session is scheduled for 10:00 a.m. Thursday, June 14, 2007.

**About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

**For more information, visit <http://www.maxcyte.com>.**

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###